272 related articles for article (PubMed ID: 23880781)
1. Efficacy and side effects of dacarbazine in comparison with temozolomide in the treatment of malignant melanoma: a meta-analysis consisting of 1314 patients.
Teimouri F; Nikfar S; Abdollahi M
Melanoma Res; 2013 Oct; 23(5):381-9. PubMed ID: 23880781
[TBL] [Abstract][Full Text] [Related]
2. Temozolomide for Treating Malignant Melanoma.
Li RH; Hou XY; Yang CS; Liu WL; Tang JQ; Liu YQ; Jiang G
J Coll Physicians Surg Pak; 2015 Sep; 25(9):680-8. PubMed ID: 26374366
[TBL] [Abstract][Full Text] [Related]
3. Efficacy and safety between temozolomide alone and temozolomide-based double therapy for malignant melanoma: a meta-analysis.
Jiang G; Li RH; Sun C; Jia HY; Lei TC; Liu YQ
Tumour Biol; 2014 Jan; 35(1):315-22. PubMed ID: 24163082
[TBL] [Abstract][Full Text] [Related]
4. Dacarbazine but not temozolomide induces phototoxic dermatitis in patients with malignant melanoma.
Treudler R; Georgieva J; Geilen CC; Orfanos CE
J Am Acad Dermatol; 2004 May; 50(5):783-5. PubMed ID: 15097966
[TBL] [Abstract][Full Text] [Related]
5. Health-related quality of life in patients with advanced metastatic melanoma: results of a randomized phase III study comparing temozolomide with dacarbazine.
Kiebert GM; Jonas DL; Middleton MR
Cancer Invest; 2003; 21(6):821-9. PubMed ID: 14735685
[TBL] [Abstract][Full Text] [Related]
6. Temozolomide with or without radiotherapy in melanoma with unresectable brain metastases.
Hofmann M; Kiecker F; Wurm R; Schlenger L; Budach V; Sterry W; Trefzer U
J Neurooncol; 2006 Jan; 76(1):59-64. PubMed ID: 16132502
[TBL] [Abstract][Full Text] [Related]
7. Randomized phase III study of temozolomide versus dacarbazine in the treatment of patients with advanced metastatic malignant melanoma.
Middleton MR; Grob JJ; Aaronson N; Fierlbeck G; Tilgen W; Seiter S; Gore M; Aamdal S; Cebon J; Coates A; Dreno B; Henz M; Schadendorf D; Kapp A; Weiss J; Fraass U; Statkevich P; Muller M; Thatcher N
J Clin Oncol; 2000 Jan; 18(1):158-66. PubMed ID: 10623706
[TBL] [Abstract][Full Text] [Related]
8. Selumetinib plus dacarbazine versus placebo plus dacarbazine as first-line treatment for BRAF-mutant metastatic melanoma: a phase 2 double-blind randomised study.
Robert C; Dummer R; Gutzmer R; Lorigan P; Kim KB; Nyakas M; Arance A; Liszkay G; Schadendorf D; Cantarini M; Spencer S; Middleton MR
Lancet Oncol; 2013 Jul; 14(8):733-40. PubMed ID: 23735514
[TBL] [Abstract][Full Text] [Related]
9. Extended schedule, escalated dose temozolomide versus dacarbazine in stage IV melanoma: final results of a randomised phase III study (EORTC 18032).
Patel PM; Suciu S; Mortier L; Kruit WH; Robert C; Schadendorf D; Trefzer U; Punt CJ; Dummer R; Davidson N; Becker J; Conry R; Thompson JA; Hwu WJ; Engelen K; Agarwala SS; Keilholz U; Eggermont AM; Spatz A;
Eur J Cancer; 2011 Jul; 47(10):1476-83. PubMed ID: 21600759
[TBL] [Abstract][Full Text] [Related]
10. Post hoc economic analysis of temozolomide versus dacarbazine in the treatment of advanced metastatic melanoma.
Hillner BE; Agarwala S; Middleton MR
J Clin Oncol; 2000 Apr; 18(7):1474-80. PubMed ID: 10735895
[TBL] [Abstract][Full Text] [Related]
11. New cytotoxic agents for the treatment of metastatic malignant melanoma: temozolomide and related alkylating agents in combination with guanine analogues to abrogate drug resistance.
Spiro T; Liu L; Gerson S
Forum (Genova); 2000; 10(3):274-85. PubMed ID: 11007934
[TBL] [Abstract][Full Text] [Related]
12. Temozolomide for the treatment of brain metastases associated with metastatic melanoma: a phase II study.
Agarwala SS; Kirkwood JM; Gore M; Dreno B; Thatcher N; Czarnetski B; Atkins M; Buzaid A; Skarlos D; Rankin EM
J Clin Oncol; 2004 Jun; 22(11):2101-7. PubMed ID: 15169796
[TBL] [Abstract][Full Text] [Related]
13. Temozolomide for the treatment of metastatic melanoma: a systematic review.
Quirt I; Verma S; Petrella T; Bak K; Charette M
Oncologist; 2007 Sep; 12(9):1114-23. PubMed ID: 17914081
[TBL] [Abstract][Full Text] [Related]
14. [Temozolomide as therapeutic option for patients with metastatic melanoma and poor prognosis].
Frick S; Lischner S; Rosien F; Haacke TC; Schäfer F; Christophers E; Hauschild A
Hautarzt; 2002 Oct; 53(10):659-65. PubMed ID: 12297947
[TBL] [Abstract][Full Text] [Related]
15. Treatment of resistant metastatic melanoma using sequential epigenetic therapy (decitabine and panobinostat) combined with chemotherapy (temozolomide).
Xia C; Leon-Ferre R; Laux D; Deutsch J; Smith BJ; Frees M; Milhem M
Cancer Chemother Pharmacol; 2014 Oct; 74(4):691-7. PubMed ID: 25062770
[TBL] [Abstract][Full Text] [Related]
16. Temozolomide in combination with celecoxib in patients with advanced melanoma. A phase II study of the Hellenic Cooperative Oncology Group.
Gogas H; Polyzos A; Stavrinidis I; Frangia K; Tsoutsos D; Panagiotou P; Markopoulos C; Papadopoulos O; Pectasides D; Mantzourani M; Middleton M; Vaiopoulos G; Fountzilas G
Ann Oncol; 2006 Dec; 17(12):1835-41. PubMed ID: 16980601
[TBL] [Abstract][Full Text] [Related]
17. Randomized phase II study of temozolomide given every 8 hours or daily with either interferon alfa-2b or thalidomide in metastatic malignant melanoma.
Danson S; Lorigan P; Arance A; Clamp A; Ranson M; Hodgetts J; Lomax L; Ashcroft L; Thatcher N; Middleton MR
J Clin Oncol; 2003 Jul; 21(13):2551-7. PubMed ID: 12829675
[TBL] [Abstract][Full Text] [Related]
18. Temozolomide associated with PEG-interferon in patients with metastatic melanoma: a multicenter prospective phase I/II study.
Guillot B; Khamari A; Cupissol D; Delaunay M; Bedane C; Dreno B; Picot MC; Dereure O
Melanoma Res; 2008 Apr; 18(2):141-6. PubMed ID: 18337651
[TBL] [Abstract][Full Text] [Related]
19. Temozolomide: a novel oral alkylating agent.
Danson SJ; Middleton MR
Expert Rev Anticancer Ther; 2001 Jun; 1(1):13-9. PubMed ID: 12113120
[TBL] [Abstract][Full Text] [Related]
20. Complete response of multiple melanoma brain metastases after treatment with temozolomide.
Dvorak J; Melichar B; Zizka J; Hadzi-Nikolov D; Petera J
Onkologie; 2004 Apr; 27(2):171-4. PubMed ID: 15138351
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]